Axium Healthcare Pharmacy Joins Merck’s Limited Distribution Network for SYLATRON™ (peginterferon alfa-2b) and INTRON® A (interferon alfa-2b, recombinant) for Injection

Axium is selected as a network provider for Merck’s limited distribution drugs SYLATRON™ and INTRON® A.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend

Lake Mary, FLA (PRWEB) February 03, 2014

Axium Healthcare Pharmacy (http://www.axiumhealthcare.com) announced today that it has been selected as a network provider for Merck’s limited distribution drugs SYLATRON™ (peginterferon alfa-2b) and INTRON® A (interferon alfa-2b, recombinant) for Injection.

SYLATRON™ is indicated for adjuvant treatment of melanoma with microscopic or gross nodal involvement within 84 days of definitive surgical resection including complete lymphadenectomy. INTRON® A for Injection is indicated as adjuvant to surgical treatment in patients 18 years of age or older with malignant melanoma who are free of disease but at high risk for systemic recurrence within 56 days of surgery. Full prescribing information for SYLATRON™ and INTRON® A for Injection is available at http://www.merck.com.

“We are pleased to be a Merck limited distribution partner,” said Axium Healthcare Pharmacy President and CEO, Mark Montgomery. “For years, Axium has specialized in providing oncology therapies and support, guiding patients and providers through the therapy management process. Our clinical expertise in oncology, combined with our world-class ‘helping hand’ therapy management programs, helps to ensure that melanoma patients can maximize the benefits of treatment with SYLATRON™ and INTRON® A.”

As a limited distribution provider of SYLATRON™ and INTRON® A, Axium will provide prescribers and patients with the benefits of its OncologyVisions® program. These benefits include:

  •     24x7x365 clinical support including patient care coordinators, registered nurses, licensed pharmacists and insurance specialists.
  •     Dedicated physician account managers.
  •     Preauthorization services.
  •     Patient copay assistance and dedicated PAP sourcing programs.
  •     Patient training and education about treatment program and medication.
  •     Side effect management.
  •     Patient compliance and adherence management.
  •     Free, quick and confidential medication delivery for patients.
  •     Anytime-anywhere patient therapy management through Axium’s OnePlace treatment management portal.
  •     Axium is e-script ready.

About Axium Healthcare Pharmacy

Founded in 2000, Axium Healthcare Pharmacy, Inc. is a nationwide provider of specialty pharmacy services. A wholly-owned subsidiary of The Kroger Company, Axium provides drug therapies and patient support services to treat chronic, genetic, and other complex conditions such as Hepatitis C, Multiple Sclerosis, Cancer, Rheumatoid Arthritis, and a number of others.

For more information, contact Axium Healthcare Pharmacy at 888.315.3395 or visit http://www.axiumhealthcare.com.

About Merck

Today's Merck is a global healthcare leader working to help the world be well. Merck is known as MSD outside the United States and Canada. Through our prescription medicines, vaccines, biologic therapies, and consumer care and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. For more information, visit http://www.merck.com and connect with us on Twitter, Facebook and YouTube.